Publications by authors named "David B Volkin"

Claim this Profile
P
PfCSP-ferritin nanoparticle malaria vaccine antigen formulated with aluminum-salt and CpG 1018® adjuvants: Preformulation characterization, antigen-adjuvant interactions, and mouse immunogenicity studies.
John M Hickey, Nitya Sharma, Max Fairlamb, Jennifer Doering, Yetunde Adewunmi, David B Volkin

Hum Vaccin Immunother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The capillary-tube-evaporative-concentration (CTEC) method: A new protein-sparing approach to directly determine protein apparent solubility values for antibody developability assessments.
Xi Luan, Kyle Camarda, Hao Lou, Scott Lovell, David B Volkin

J Pharm Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody signatures elicited by potent and subpotent whole-cell pertussis vaccines in mice.
Yetunde Adewunmi, Jennifer Doering, Prashant Kumar, Jozelyn V Pablo, Andy A Teng, David B Volkin

Microbiol Spectr· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two recombinant cytomegalovirus antigens formulated with the SPA14 adjuvant system: Impact of temperature, pH and excipients on the stability of each antigen and adjuvant component.
John M Hickey, Ozan S Kumru, François Dalençon, Florence Arvis, Charles Lutsch, David B Volkin

J Pharm Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Compatibility of Three Aluminum Salt-Adjuvanted Recombinant Protein Antigens (Trivalent NRRV) Combined with a Mock Trivalent Sabin-IPV Vaccine: Analytical and Formulation Challenges.
Prashant Kumar, Atsushi Hamana, Christopher Bird, Brandy Dotson, Soraia Saleh-Birdjandi, David B Volkin

Vaccines (Basel)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal purification method enables developability assessment of recombinant proteins.
Sergio A Rodriguez-Aponte, Christopher A Naranjo, Ryan S Johnston, Neil C Dalvie, Laura E Crowell, David B Volkin

Biotechnol Bioeng· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges.
Prashant Kumar, David A Holland, Kathryn Secrist, Poorva Taskar, Brandy Dotson, David B Volkin

Vaccines (Basel)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Combined LC-MS and Immunoassay Approach to Characterize Preservative-Induced Destabilization of Human Papillomavirus Virus-like Particles Adsorbed to an Aluminum-Salt Adjuvant.
Ria T Caringal, John M Hickey, Nitya Sharma, Kaushal Jerajani, Oluwadara Bewaji, David B Volkin

Vaccines (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
Ozan S Kumru, Mrinmoy Sanyal, Natalia Friedland, John M Hickey, Richa Joshi, David B Volkin

Vaccine· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.
Payton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogeng Tang, Prabhu S Arunachalam, David B Volkin

Nat Commun· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate.
Prashant Kumar, Michael Wang, Ozan S Kumru, John M Hickey, Julio Sanmiguel, David B Volkin

Mol Ther Methods Clin Dev· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).
Ozan S Kumru, Sakshi Bajoria, Kawaljit Kaur, John M Hickey, Greta Van Slyke, David B Volkin

Hum Vaccin Immunother· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formulation Studies to Develop Low-Cost, Orally-Delivered Secretory IgA Monoclonal Antibodies for Passive Immunization Against Enterotoxigenic Escherichia coli.
Sakshi Bajoria, Lorena R Antunez, Ozan S Kumru, Mark Klempner, Yang Wang, David B Volkin

J Pharm Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018 Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen.
Sakshi Bajoria, Ozan S Kumru, Jennifer Doering, Katherine Berman, Greta Van Slyke, David B Volkin

Vaccines (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurement of Adenovirus-Based Vector Heterogeneity.
John M Hickey, Shaleem I Jacob, Andrew S Tait, Fatemeh Dastjerdi Vahid, Joseph Barritt, David B Volkin

J Pharm Sci· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
Ozan S Kumru, Mrinmoy Sanyal, Natalia Friedland, John Hickey, Richa Joshi, David B Volkin

bioRxiv· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.
Payton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogeng Tang, Prabhu S Arunachalam, David B Volkin

Nat Commun· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Protein Particle Formation in IgG1 mAbs Formulated with PS20 Vs. PS80 When Subjected to Interfacial Dilatational Stress.
Coleman Vaclaw, Kimberly Merritt, Valerie P Griffin, Neal Whitaker, Madhushree Gokhale, David B Volkin

AAPS PharmSciTech· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative Combinations.
Kaushal Jerajani, Ying Wan, Ozan S Kumru, Swathi R Pullagurla, Prashant Kumar, David B Volkin

J Pharm Sci· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case.
Erik Oude Blenke, Eivor Örnskov, Christian Schöneich, Gunilla A Nilsson, David B Volkin

J Pharm Sci· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part II- Real-time and Accelerated Stability Studies.
Nitya Sharma, Kaushal Jerajani, Ying Wan, Ozan S Kumru, Swathi R Pullagurla, David B Volkin

J Pharm Sci· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants.
Sergio A Rodriguez-Aponte, Neil C Dalvie, Ting Y Wong, Ryan S Johnston, Christopher A Naranjo, David B Volkin

Vaccine· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.
Prashant Kumar, Christopher Bird, David Holland, Sangeeta B Joshi, David B Volkin

Hum Vaccin Immunother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.
Payton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogeng Tang, Prabhu S Arunachalam, David B Volkin

bioRxiv· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developability Assessments of Monoclonal Antibody Candidates to Minimize Aggregation During Large-Scale Ultrafiltration and Diafiltration (UF-DF) Processing.
Neal Whitaker, Samantha E Pace, Kimberly Merritt, Madeleine Tadros, Mehrnaz Khossravi, David B Volkin

J Pharm Sci· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis